Friday, July 10, 2026
🇺🇸 FDA

pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma

Ningbo Cancer Hospital

Ningbo Cancer Hospital drug portfolio — 183 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
120
Drugs
183
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

Ningbo Cancer Hospital pipeline

Portfolio lens on 183 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Ningbo Cancer Hospital drug portfolio — 183 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

183 compounds

  1. abemaciclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  2. abiraterone

    Antineoplastic and immunomodulating agents (L02)

    Antineoplastic and immunomodulating agents (L02) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Steroid 5-alpha-reductase inhibitor

  3. abiraterone acetate

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.

    Target
    Steroid 17-alpha-hydroxylase/17,20 lyase
    Mechanism
    Cytochrome P450 17A1 inhibitor

  4. abraxane

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  5. acalabrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  6. administration

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  7. alpelisib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.

    Target
    Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
    Mechanism
    PI3-kinase p110-alpha subunit inhibitor

  8. anastrozole

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  9. antagonist

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  10. apalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  11. aprepitant

    Alimentary tract and metabolism (A04)

    US regulatory status: approved. Molecular target: Substance-P receptor.

    Target
    Substance-P receptor
    Mechanism
    Neurokinin 1 receptor antagonist

  12. asenapine

    Nervous system (N05)

    US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.

    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  13. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  14. atropine sulfate

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  15. avelumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 other

  16. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  17. bicalutamide

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  18. binimetinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

  19. biological

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  20. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  21. brentuximab vedotin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  22. cabazitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  23. calcium

    US regulatory status: approved.

  24. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  25. capsule

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  26. capsules

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  27. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  28. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  29. cells

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  30. cemiplimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  31. cerivastatin sodium

    US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

    Target
    3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Mechanism
    HMG-CoA reductase inhibitor

  32. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  33. chemotherapy

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  34. chloride

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  35. chlorpheniramine

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  36. chlorpheniramine maleate

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  37. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  38. clobazam

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  39. cobimetinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

  40. combination

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  42. control

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  43. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  44. dacarbazine

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  45. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  46. darolutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  47. degarelix

    Antineoplastic and immunomodulating agents (L02)

    Antineoplastic and immunomodulating agents (L02) compound in Ningbo Cancer Hospital's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.

    Mechanism
    Gonadotropin-releasing hormone receptor antagonist

  48. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  49. dexchlorpheniramine maleate

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  50. dexrazoxane

    Various (V03)

    Various (V03) compound in Ningbo Cancer Hospital's portfolio. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  51. dexrazoxane hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  52. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  53. dostarlimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 antagonist

  54. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  55. doxorubicin hydrochloride

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA topoisomerase II alpha inhibitor

  56. duloxetine

    Nervous system (N06)

    Nervous system (N06) compound in Ningbo Cancer Hospital's portfolio. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  57. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  58. edotreotide

    Various (V09)

    Various (V09) compound in Ningbo Cancer Hospital's portfolio.

  59. encorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.

    Target
    Serine/threonine-protein kinase B-raf
    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  60. endocrine

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  61. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  62. epirubicin

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  63. epithelial

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  64. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  65. ethiodized oil

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  66. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  67. etoposide-cisplatin

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  68. everolimus

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  69. exemestane

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  70. filgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  71. fluconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  72. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  73. flutamide

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  74. folinic acid

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  75. fulvestrant

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor antagonist

  76. furosemide

    Cardiovascular system (C03)

    US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.

    Target
    Solute carrier family 12 member 1
    Mechanism
    Sodium-(potassium)-chloride cotransporter 2 inhibitor

  77. futibatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Fibroblast growth factor receptor.

    Target
    Fibroblast growth factor receptor
    Mechanism
    Fibroblast growth factor receptor inhibitor

  79. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  80. goserelin

    US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.

    Mechanism
    Gonadotropin-releasing hormone receptor agonist

  81. goserelin acetate

    US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.

    Target
    Gonadotropin-releasing hormone receptor
    Mechanism
    Gonadotropin-releasing hormone receptor agonist

  82. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  83. hydrogen

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  84. hydroxycarbamide

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.

    Target
    Ribonucleoside-diphosphate reductase RR1
    Mechanism
    Ribonucleoside-diphosphate reductase RR1 inhibitor

  85. hydroxychloroquine

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.

    Mechanism
    Toll-like receptor 7 antagonist

  86. hydroxychloroquine sulfate

    US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.

    Target
    Ferriprotoporphyrin IX
    Mechanism
    Toll-like receptor 9 antagonist

  87. idarubicin

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  88. ifosfamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  89. immunotherapy

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  90. infusion

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  91. inhibitor

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  92. inhibitors

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  93. injectable

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  94. injection

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  95. ipilimumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  96. irinotecan

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  97. isatuximab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  98. ivonescimab

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  99. ivosidenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.

    Target
    Isocitrate dehydrogenase [NADP] cytoplasmic
    Mechanism
    Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor

  100. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  101. letrozole

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  102. leucovorin

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  103. leuprorelin

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  104. levoleucovorin

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  105. lomustine

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  106. lutetium (177lu) oxodotreotide

    Various (V10)

    Various (V10) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Somatostatin receptor.

    Target
    Somatostatin receptor
    Mechanism
    Somatostatin receptor binding agent

  108. maintenance

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  109. mesna

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  110. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  111. methylprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  112. mifamurtide

    Antineoplastic and immunomodulating agents (L03)

    Antineoplastic and immunomodulating agents (L03) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Nucleotide-binding oligomerization domain-containing protein 2.

    Target
    Nucleotide-binding oligomerization domain-containing protein 2
    Mechanism
    Nucleotide-binding oligomerization domain-containing protein 2 other

  113. mitomycin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  114. mitotane

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cholesterol side-chain cleavage enzyme, mitochondrial.

    Target
    Cholesterol side-chain cleavage enzyme, mitochondrial
    Mechanism
    Cytochrome P450 11B1 inhibitor

  115. mogamulizumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: C-C chemokine receptor type 4.

    Target
    C-C chemokine receptor type 4
    Mechanism
    C-C chemokine receptor type 4 cross-linking agent

  116. molecular

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  117. monotherapy

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  118. neoadjuvant

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  119. neratinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  120. niraparib tosilate hydrate

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.

    Target
    Poly [ADP-ribose] polymerase 2
    Mechanism
    Poly [ADP-ribose] polymerase 2 inhibitor

  121. nivolumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  122. octreotide

    Systemic hormonal preparations (H01)

    Systemic hormonal preparations (H01) compound in Ningbo Cancer Hospital's portfolio. Mechanism: Somatostatin receptor agonist.

    Mechanism
    Somatostatin receptor agonist

  123. olaparib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: PARP 1, 2 and 3.

    Target
    PARP 1, 2 and 3
    Mechanism
    PARP 1, 2 and 3 inhibitor

  124. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  125. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  126. palbociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CDK6/cyclin D1.

    Target
    CDK6/cyclin D1
    Mechanism
    Cyclin-dependent kinase 4/cyclin D1 inhibitor

  127. panitumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  128. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  129. pemetrexed

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  130. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  131. pemigatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Fibroblast growth factor receptor 1.

    Target
    Fibroblast growth factor receptor 1
    Mechanism
    Fibroblast growth factor receptor 1 inhibitor

  132. peritoneal

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  133. pertuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  134. placebo

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  135. pomalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  136. ponatinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Mechanism: Bcr/Abl fusion protein inhibitor.

    Mechanism
    Bcr/Abl fusion protein inhibitor

  137. ponatinib hydrochloride

    US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.

    Target
    Bcr/Abl fusion protein
    Mechanism
    Bcr/Abl fusion protein inhibitor

  138. potassium chloride

    US regulatory status: approved. Mechanism: Supplement.

    Mechanism
    Supplement

  139. powder

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  140. precision

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  141. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  142. progression

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  143. propylthiouracil

    US regulatory status: approved. Molecular target: Thyroid peroxidase.

    Target
    Thyroid peroxidase
    Mechanism
    Thyroid peroxidase inhibitor

  144. radium ra223 dichloride

    Various (V10)

    Various (V10) compound in Ningbo Cancer Hospital's portfolio. Mechanism: Radiotherapy agent.

    Mechanism
    Radiotherapy agent

  145. ranitidine

    US regulatory status: approved. Molecular target: Histamine H2 receptor.

    Target
    Histamine H2 receptor
    Mechanism
    Histamine H2 receptor antagonist

  146. regorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.

    Target
    Discoidin domain-containing receptor 2
    Mechanism
    Fibroblast growth factor receptor 2 inhibitor

  147. relatlimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Lymphocyte activation gene 3 protein.

    Target
    Lymphocyte activation gene 3 protein
    Mechanism
    Lymphocyte activation gene 3 protein inhibitor

  148. relugolix

    Systemic hormonal preparations (H01)

    US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.

    Target
    Gonadotropin-releasing hormone receptor
    Mechanism
    Gonadotropin-releasing hormone receptor antagonist

  149. ribociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  150. ribociclib succinate

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 4 inhibitor

  151. sacituzumab

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  152. sacituzumab govitecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  153. solution

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  154. solvent

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  155. sonidegib phosphate

    US regulatory status: approved. Molecular target: Protein smoothened.

    Target
    Protein smoothened
    Mechanism
    Smoothened homolog inhibitor

  156. standard

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  157. stro-

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  158. sunitinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  159. syrup

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  160. tablet

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  161. tablets

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  162. tamoxifen

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.

    Mechanism
    Estrogen receptor alpha modulator

  163. targeted

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  164. tebentafusp

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Melanocyte protein PMEL.

    Target
    Melanocyte protein PMEL
    Mechanism
    Melanocyte protein PMEL binding agent

  165. therapy

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  166. tislelizumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  167. trabectedin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  168. trametinib dimethyl sulfoxide

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

  169. trastuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  170. trastuzumab deruxtecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  171. trastuzumab emtansine

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Tubulin inhibitor

  172. trastuzumab-qyyp

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  173. treatment

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records.

  174. tremelimumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Ningbo Cancer Hospital's portfolio. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  175. trifluridine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  176. triptorelin

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Gonadotropin-releasing hormone receptor agonist.

    Mechanism
    Gonadotropin-releasing hormone receptor agonist

  177. triptorelin pamoate

    US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.

    Target
    Gonadotropin-releasing hormone receptor
    Mechanism
    Gonadotropin-releasing hormone receptor agonist

  178. tucatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  179. vemurafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.

    Target
    Serine/threonine-protein kinase B-raf
    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  180. vinblastine

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Tubulin inhibitor.

    Mechanism
    Tubulin inhibitor

  181. vincristine

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Tubulin inhibitor.

    Mechanism
    Tubulin inhibitor

  182. vinorelbine

    Development asset linked to Ningbo Cancer Hospital in public FDA and regional records. Mechanism: Tubulin inhibitor.

    Mechanism
    Tubulin inhibitor

  183. zoledronic acid

    Musculo-skeletal system (M05)

    US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.

    Target
    Farnesyl pyrophosphate synthase
    Mechanism
    Farnesyl diphosphate synthase inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.